

3101 or [darakn@mail.nih.gov](mailto:darakn@mail.nih.gov) for more information.

### **mFPR2 Transgenic and Knockout Mouse Models for Alzheimer's and Other Inflammatory Diseases**

**Description of Invention:** Human Formyl Peptide-Like Receptor 1 (hFPLR1) has been implicated in host defense for disease processes including Alzheimer's disease, infection, and other inflammatory diseases. hFPLR1 and its mouse homologue Formyl Peptide Receptor 2 (mFPR2) are G-protein coupled receptors that are expressed at high levels on phagocytic leukocytes, mediating leukocyte chemotaxis and activation in response to a number of pathogen- and host-derived peptides. Activation of hFPLR1/mFPR2 by lipoxin A4 may play a role in preventing and resolving inflammation. Also, hFPLR1/mFPR2 has been shown to mediate the chemotactic activity of amyloid beta 1-42, a key pathogenic peptide in Alzheimer's disease.

Available for licensing are mice expressing the mFPR2 transgene on either the FVB or C58BL background, as well as mFPR2 knockout mice on the C57BL background. These mice are anticipated to be highly useful in the study of a wide variety of inflammatory, infectious, immunologic and neurodegenerative diseases.

#### **Applications**

- Drug development model for Alzheimer's disease and other inflammatory diseases.
- Tool to probe the role of hFPLR1/mFPR2 in host responses in a variety of disease processes, including inflammatory, infectious, immunologic, and neurodegenerative disease.

**Inventors:** Ji Ming Wang *et al.* (NCI)

#### **Publications**

1. K Chen, Y Le, Y Liu, W Gong, G Ying, J Huang, T Yoshimura, L Tessarollo, JM Wang. Cutting Edge: A Critical Role for the G Protein-Coupled Receptor mFPR2 in Airway Inflammation and Immune Responses. *J Immunol.* 2010 Mar 3. Epub ahead of print. [PubMed: 20200280.]

2. K Chen, P Iribarren, J Hu, J Chen, W Gong, EH Cho, S Lockett, NM Dunlop, and JM Wang. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. *J Biol Chem.* 2006 Feb 10;281(6):3651–3659. [PubMed: 16339765.]

3. H Yazawa, ZX Yu, Takeda, Y Le, W Gong, VJ Ferrans, JJ Oppenheim, CC Li, and JM Wang. Beta amyloid peptide (A $\beta$ 42) is internalized via the G-

protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. *FASEB J.* 2001 Nov;15(13):2454–2462. [PubMed: 11689470.]

4. YH Cui, Y Le, W Gong, P Proost, J Van Damme, WJ Murphy, and JM Wang. Bacterial lipopolysaccharide selectively up-regulates the function of the chemotactic peptide receptor formyl peptide receptor 2 in murine microglial cells. *J Immunol.* 2002 Jan 1;168(1):434–442. [PubMed: 11751990.]

**Patent Status:** HHS Reference No. E-303-2006/0—Research Tool. Patent protection is not being pursued for this technology.

**Licensing Status:** This technology is available as a research tool under a Biological Materials License.

**Licensing Contact:** Tara Kirby, PhD; 301-435-4426; [tarak@mail.nih.gov](mailto:tarak@mail.nih.gov).

**Collaborative Research Opportunity:** The National Cancer Institute—Frederick, Laboratory of Molecular Immunoregulation, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize mFPR2 Transgenic and Knockout Mouse Models for Alzheimer's and Other Inflammatory Diseases. Please contact John D. Hewes, PhD at 301-435-3121 or [hewesj@mail.nih.gov](mailto:hewesj@mail.nih.gov) for more information.

Dated: March 23, 2010.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2010-6966 Filed 3-29-10; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which

would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Ancillary Studies in Immunomodulation Clinical Trials.

**Date:** April 22, 2010.

**Time:** 11:30 a.m. to 4:30 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817. (Telephone Conference Call)

**Contact Person:** Paul A. Amstad, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892-7616, 301-402-7098, [pamstad@niaid.nih.gov](mailto:pamstad@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: March 24, 2010.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2010-7089 Filed 3-29-10; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute of Allergy and Infectious Diseases; Notice of Meeting**

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the AIDS Research Advisory Committee, NIAID.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

**Name of Committee:** AIDS Research Advisory Committee, NIAID, AIDS Vaccine Research Subcommittee.

**Date:** May 25–26, 2010.

**Time:** 8:30 a.m. to 5 p.m.

**Agenda:** To discuss follow-up studies to the recent RV144 vaccine efficacy trial, and to discuss the use of the nonhuman primate model in AIDS vaccine research.

**Place:** Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

**Contact Person:** James A. Bradac, PhD, Program Official, Preclinical Research and Development Branch, Division of AIDS, Room 5116, National Institutes of Health/ NIAID, 6700B Rockledge Drive, Bethesda, MD 20892-7628. 301-435-3754. [jbradac@mail.nih.gov](mailto:jbradac@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: March 24, 2010.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2010-7119 Filed 3-29-10; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Cancer Biology.

*Date:* April 26, 2010.

*Time:* 3 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call)

*Contact Person:* Manzoor Zarger, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6208, MSC 7804, Bethesda, MD 20892, (301) 435-2477, [zargerma@csr.nih.gov](mailto:zargerma@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 24, 2010.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2010-7087 Filed 3-29-10; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Mental Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Subcommittee for Planning the Annual Strategic Planning Process of the Interagency Autism Coordinating Committee (IACC).

The purpose of the Subcommittee for Planning the Annual Strategic Planning Process is to plan the process for updating the IACC Strategic Plan for Autism Spectrum Disorder Research. The Subcommittee meeting will be conducted as a telephone conference call. This meeting is open to the public through a conference call phone number.

*Name of Committee:* Interagency Autism Coordinating Committee (IACC).

*Type of Meeting:* Subcommittee for Planning the Annual Strategic Planning Process.

*Date:* April 19, 2010.

*Time:* 10 a.m. to 12 p.m. Eastern Time.

*Agenda:* The IACC Subcommittee for Planning the Annual Strategic Planning Process will discuss plans for updating the IACC Strategic Plan for ASD Research.

*Place:* No in-person meeting; conference call only.

*Conference Call:* Dial: 888-577-8995, Access code: 1991506.

*Contact Person:* Ms. Lina Perez, Office of Autism Research Coordination, Office of the Director, National Institute of Mental Health, NIH, 6001 Executive Boulevard, NSC, Room 8200, Bethesda, MD 20892-9669, Phone: (301) 443-6040, [IACCPublicInquiries@mail.nih.gov](mailto:IACCPublicInquiries@mail.nih.gov).

#### Please Note:

The meeting will be open to the public through a conference call phone number. Individuals who participate using this service and who need special assistance, such as captioning of the conference call or other reasonable accommodations, should submit a request at least 10 days prior to the meeting.

Members of the public who participate using the conference call phone number will be able to listen to the meeting but will not be heard.

Information about the IACC is available on the Web site: <http://www.iacc.hhs.gov>.

Dated: March 23, 2010.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2010-6972 Filed 3-29-10; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of Biotechnology Activities; Office of Science Policy; Office of the Director; Notice of a Meeting of the NIH Blue Ribbon Panel

The purpose of this notice is to inform the public about a meeting of the NIH Blue Ribbon Panel to Advise on the Risk Assessment of the National Emerging Infectious Diseases Laboratories at Boston University Medical Center. The meeting will be held on Wednesday, April 28, 2010, at the Boston Marriott Copley Place, 110 Huntington Avenue, Boston, Massachusetts 02116 from approximately 6:30 p.m. to 9:45 p.m.

The Blue Ribbon Panel is holding a public meeting to update the community on the status and proposed approach of the study. The meeting program will include presentations providing an overview of the risk assessment process, as well as breakout sessions in which more detailed presentations and dialogue about the proposed approach will take place.

Members of the public may, at any time, file written comments to the following address: NIH Blue Ribbon Panel, Office of the Director, National Institutes of Health, Mail Stop Code 7985, Bethesda, MD 20892-7985 or by sending an e-mail to: [nihb\\_brp@od.nih.gov](mailto:nihb_brp@od.nih.gov).

An agenda and slides for the meeting may be obtained prior to the meeting by connecting to <http://nihblueribbonpanel-bumc-neidl.od.nih.gov/>. For additional information concerning this meeting, please contact Ms. Laurie Lewallen, Advisory Committee Coordinator, Office of Biotechnology Activities, Office of Science Policy, Office of the Director, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892-7985; telephone 301-496-9838; e-mail [lewallenl@od.nih.gov](mailto:lewallenl@od.nih.gov).

Dated: March 24, 2010.

**Amy P. Patterson,**

*Director, Office of Biotechnology Activities, National Institutes of Health.*

[FR Doc. 2010-6970 Filed 3-29-10; 8:45 am]

**BILLING CODE 4140-01-P**